Search

Search Constraints

You searched for: Author/Creator Binks, Michael

Search Results

2. Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials. Issue 9 (September 2022)

3. Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID‐19 Trial of Nirmatrelvir. Issue 1 (4th May 2022)

4. Panel 4: Recent advances in understanding the natural history of the otitis media microbiome and its response to environmental pressures. (March 2020)

5. Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID‐19, in Subjects With Renal Impairment. Issue 4 (5th July 2022)

7. Safety, Tolerability, and Pharmacokinetics of Intravenous Doses of PF‐07304814, a Phosphate Prodrug Protease Inhibitor for the Treatment of SARS‐CoV‐2, in Healthy Adult Participants. Issue 12 (26th October 2022)

8. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Domagrozumab (PF‐06252616), an Antimyostatin Monoclonal Antibody, in Healthy Subjects. Issue 5 (7th September 2017)

9. Transplacental transfer of RSV antibody in Australian First Nations infants. Issue 2 (16th October 2021)